trazodone and Acute Confusional Senile Dementia studies

Trazodone: A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309)
trazodone : An N-arylpiperazine in which one nitrogen is substituted by a 3-chlorophenyl group, while the other is substituted by a 3-(3-oxo[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)propyl group.

Research Excerpts

Excerpt	Relevance	Reference
"There are no randomized clinical trials regarding efficacy of trazodone in the treatment of sleep disturbances (SD) in patients with Alzheimer disease (AD)."	9.19	Trazodone improves sleep parameters in Alzheimer disease patients: a randomized, double-blind, and placebo-controlled study. ( Camargos, EF; Louzada, FM; Louzada, LL; Naves, JO; Nóbrega, OT; Quintas, JL, 2014)
"So, trazodone appears to produce a stabilization of the circadian rhythms in individuals with AD."	6.80	Circadian rhythm in Alzheimer disease after trazodone use. ( Camargos, EF; Gonçalves, BS; Grippe, TC; Louzada, LL; Naves, JO; Nóbrega, OT; Quintas, JL, 2015)
"There are no randomized clinical trials regarding efficacy of trazodone in the treatment of sleep disturbances (SD) in patients with Alzheimer disease (AD)."	5.19	Trazodone improves sleep parameters in Alzheimer disease patients: a randomized, double-blind, and placebo-controlled study. ( Camargos, EF; Louzada, FM; Louzada, LL; Naves, JO; Nóbrega, OT; Quintas, JL, 2014)
"To examine the effect of galantamine in elderly patients with mild to moderate Alzheimer disease (AD) on reaction time (RT), selective (SA) and alternating attention (AA), errors, and on interindividual and intraindividual variability."	5.12	The influence of galantamine on reaction time, attention processes, and performance variability in elderly Alzheimer patients. ( De Raedt, R; Gorus, E; Lambert, M; Mets, T, 2007)
" In this equivalence study the effect of 5'-MTHF on depressive symptoms and cognitive status was compared to Trazodone (TRZ) in normofolatemic elderly patients with mild to moderate dementia and depression."	5.07	Oral 5'-methyltetrahydrofolic acid in senile organic mental disorders with depression: results of a double-blind multicenter study. ( Abate, G; Cucinotta, D; Diana, R; La Greca, P; Le Grazie, C; Passeri, M; Senin, U; Stramba Badiale, M; Ventura, A, 1993)
" TRAZODONE: Studies conducted in patients with Alzheimer's disease, mixed type dementia, or fronto-temporal dementia have shown the efficacy of trazodone for diverse types of symptoms: sadness, emotional disorders, irritability, fear, psychomotor instability, delirant ideas."	4.82	[Serotonin reuptake inhibitors in depression of Alzheimer's disease and other dementias]. ( Lebert, F, 2003)
"This retrospective study examines whether long-term use of trazodone, an SWS enhancer, is associated with delayed cognitive decline."	3.91	Long-Term Trazodone Use and Cognition: A Potential Therapeutic Role for Slow-Wave Sleep Enhancers. ( Karageorgiou, E; Krystal, AD; La, AL; Miller, BL; Neylan, TC; Vossel, KA; Walsh, CM; Yaffe, K, 2019)
"So, trazodone appears to produce a stabilization of the circadian rhythms in individuals with AD."	2.80	Circadian rhythm in Alzheimer disease after trazodone use. ( Camargos, EF; Gonçalves, BS; Grippe, TC; Louzada, LL; Naves, JO; Nóbrega, OT; Quintas, JL, 2015)
" In a 9 week dosing regimen, trazodone decreased microglial NLRP3 inflammasome expression and phosphorylated p38 mitogen-activated protein kinase levels, which correlated with the NLRP3 inflammasome, the UPR effector ATF4, and total tau levels."	1.72	Improved Sleep, Memory, and Cellular Pathological Features of Tauopathy, Including the NLRP3 Inflammasome, after Chronic Administration of Trazodone in rTg4510 Mice. ( Cella, C; de Oliveira, P; Dijk, DJ; Gilmour, G; Locker, N; Mendis, A; Ravindran, KKG; Wafford, K; Winsky-Sommerer, R, 2022)
"Trazodone has a variety of effects on several monoaminergic mechanisms: a potent serotonin 5-HT2A and α1-adrenergic receptor antagonist, a weak serotonin reuptake inhibitor, and a weak antihistamine or histamine H1 receptor inverse agonist."	1.51	Treatment of Alzheimer's Disease: Trazodone, Sleep, Serotonin, Norepinephrine, and Future Directions. ( Ashford, JW, 2019)
" Chronic administration of the synthetic gonadotropin (luteinising hormone) releasing hormone analogue, goserelin, reduces testosterone activity."	1.33	Gonadotrophin-releasing hormone agonist treatment of aggression in Alzheimer's disease: a case report. ( Raskind, MA; Rosin, RA, 2005)

Research

Studies (30)

Authors

Clinical Trials (16)

Trial Overview

Trial Outcomes

Change From Baseline to 24 Weeks in ADAS-cog

Timeframe	Studies, this research(%)	All Research%
pre-1990	2 (6.67)	18.7374
1990's	5 (16.67)	18.2507
2000's	11 (36.67)	29.6817
2010's	9 (30.00)	24.3611
2020's	3 (10.00)	2.80

Authors	Studies
de Oliveira, P	1
Cella, C	1
Locker, N	1
Ravindran, KKG	1
Mendis, A	1
Wafford, K	1
Gilmour, G	1
Dijk, DJ	1
Winsky-Sommerer, R	1
Akbari, V	1
Ghobadi, S	1
Mohammadi, S	1
Khodarahmi, R	1
McCleery, J	3
Sharpley, AL	3
Boccardi, V	1
Baroni, M	1
Paolacci, L	1
Ercolani, S	1
Longo, A	1
Giordano, M	1
Ruggiero, C	1
Mecocci, P	1
Raglio, A	1
Filippi, S	1
Leonardelli, L	1
Trentini, E	1
Bellandi, D	1
La, AL	1
Walsh, CM	1
Neylan, TC	1
Vossel, KA	1
Yaffe, K	1
Krystal, AD	1
Miller, BL	1
Karageorgiou, E	1
Ashford, JW	1
Camargos, EF	3
Louzada, LL	3
Quintas, JL	3
Naves, JO	3
Louzada, FM	1
Nóbrega, OT	3
Cohen, DA	2
Furioso, AC	1
Grippe, TC	1
Gonçalves, BS	1
Lebert, F	2
Cummings, JL	1
Tractenberg, RE	3
Gamst, A	2
Teri, L	3
Masterman, D	1
Thal, LJ	3
Rosin, RA	1
Raskind, MA	1
Kitamura, Y	1
Kudo, Y	1
Imamura, T	1
Gorus, E	1
Lambert, M	1
De Raedt, R	1
Mets, T	1
Le Ber, I	1
Dubois, B	1
Pasquier, F	1
Petit, H	1
Passeri, M	1
Cucinotta, D	1
Abate, G	1
Senin, U	1
Ventura, A	1
Stramba Badiale, M	1
Diana, R	1
La Greca, P	1
Le Grazie, C	1
Galluzzi, S	1
Zanetti, O	1
Binetti, G	1
Trabucchi, M	1
Frisoni, GB	1
Logsdon, RG	1
Peskind, E	1
Raskind, M	1
Weiner, MF	2
Foster, NL	1
Schneider, LS	2
Sano, M	2
Whitehouse, P	1
Tariot, P	1
Mellow, AM	1
Auchus, AP	1
Grundman, M	1
Thomas, RG	1
Schafer, K	1
Sultzer, DL	1
Gray, KF	1
Gunay, I	1
Wheatley, MV	1
Mahler, ME	1
González Moneo, MJ	1
Garrido Barral, A	1
Logsdon, R	1
Galasko, D	1
Thomas, R	1
Sobin, PB	1
Hawkins, JW	1
Gedye, A	1
Maletta, GJ	1
Simpson, DM	1
Foster, D	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Mirtazapine for the Treatment of Sleep Disorders in Alzheimer's Disease: a Randomized, Double-blind, Placebo-controlled Study[NCT01867775]	Phase 3	30 participants (Anticipated)	Interventional	2012-05-31	Recruiting
A Randomized Placebo-controlled Trial Evaluating the Effect of Melatonin on Sleep Quality in Patients With Dementia[NCT03066518]	Phase 4	40 participants (Actual)	Interventional	2016-01-15	Completed
Phase IV Study Safety & Feasibility of Sodium Oxybate in Mild Alzheimer's Disease Patients.[NCT00706186]	Phase 4	4 participants (Actual)	Interventional		Terminated (stopped due to Withdrawn by Investigator, protocol in revision)
[NCT00000171]	Phase 3	0 participants	Interventional		Completed
A Double-blind, Randomized Pilot Study to Evaluate the Effects of Galantamine and Donepezil on Sleep and Attention and Gastrointestinal (GI) Tolerance in Patients With Mild to Moderate Alzheimer's Disease (AD)[NCT00035204]	Phase 4	63 participants (Actual)	Interventional		Completed
A Double-blind, Parallel Group, Randomized, Placebo Controlled Study of the Efficacy of Circadin® 2mg in Patients With Mild to Moderate Alzheimer Disease (AD) Treated With Acetylcholinesterase (AChE) Inhibitor[NCT00940589]	Phase 2	73 participants (Actual)	Interventional	2009-09-30	Completed
A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of 8 Week Treatment of Rozerem 8 mg (QHS) in Sleep Disturbed, Mild to Moderately Severe Alzheimer's Disease Subjects[NCT00325728]	Phase 2	74 participants (Actual)	Interventional	2006-03-21	Completed
The Effect of Anticholinesterase Drugs on Sleep in Alzheimer's Disease Patients[NCT00480870]	Phase 4	65 participants (Actual)	Interventional	1999-04-30	Completed
Modafinil Treatment for Sleep/Wake Disturbances in Older Adults[NCT00626210]	Phase 4	2 participants (Actual)	Interventional	2008-02-29	Terminated
Does Zolpidem CR Treatment Change Clinical Outcomes in Elderly Hospitalized Patients With Dementia- A Pilot Study[NCT00814502]		20 participants (Actual)	Interventional	2008-12-31	Completed
Efficacy of Pain Treatment on Depression in Patients With Dementia. A Randomized Clinical Trial.[NCT02267057]	Phase 4	163 participants (Actual)	Interventional	2014-08-31	Completed
Trazodone for the Treatment of Sleep Disorders in Alzheimer's Disease: a Randomised, Double-blind, Placebo-controlled Study[NCT01142258]	Phase 3	40 participants (Actual)	Interventional	2010-03-31	Completed
A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Subjects With Alzheimer's Disease[NCT02750306]	Phase 3	285 participants (Actual)	Interventional	2016-05-23	Completed
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild t[NCT01266525]	Phase 2	291 participants (Actual)	Interventional	2011-02-28	Completed
A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Placebo-Controlled[NCT01548287]	Phase 2	164 participants (Actual)	Interventional	2012-04-30	Completed
[NCT00000179]	Phase 3	0 participants	Interventional		Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

ADAS-cog (Alzheimer's Disease Assessment Scale-cognitive subscale) is a cognitive testing instrument used in clinical trials. It consists of 11 tasks measuring the disturbances of memory, language, praxis, attention, and other cognitive abilities that are often referred to as the core symptoms of AD. The test comprises 11 items summed to a total score ranging from 0 to 70, with lower scores indicating less severe impairment. A negative change indicates an improvement from baseline. ADAS-cog was measured at base line and at end of treatment after 24 weeks. (NCT00940589)
Timeframe: 24 weeks

Change From Baseline to 24 Weeks in iADL

Intervention	Scores on a scale (Mean)
Circadin	0.45
Placebo	0.19

Instrumental Activities of Daily Living (iADL). The scale rates activities that represent key life tasks that people need to manage. These tasks are valuable for evaluating persons with early-stage disease, both to assess the level of disease and to determine the person's ability to care for himself or herself. Scores of 0 or 1 are given to every task (Bathing, Dressing, Tolieting, transferring, Continence and Feeding) to a total score of 6. , while 0 represents a patient who is very dependent and 6 represents patient who is independent. iADL was measured at base line and at end of treatment after 24 weeks. (NCT00940589)
Timeframe: 24 weeks

Change From Baseline to 24 Weeks in MMSE

Intervention	Scores on a scale (Mean)
Circadin	0.77
Placebo	1.62

The Mini Mental State Examination (MMSE) is a brief assessment instrument used to assess cognitive function in elderly patients. The MMSE can be used to screen for cognitive impairment and as a measurement of cognition over time and with pharmacologic treatment. The instrument is divided into 2 sections. The first section measures orientation, memory, and attention: the maximum score is 21. The second section tests the ability of the patient to name objects, follow verbal and written commands, write a sentence, and copy figures: the maximum score is 9. The scoring range for the MMSE is 0-30. Higher score represents better performance. MMSE was measured at base line and at end of treatment after 24 weeks. (NCT00940589)
Timeframe: 24 weeks

Nocturnal Sleep Length at 1 Month

Sleep Efficiency

Intervention	Scores on a scale (Mean)
Circadin	-0.3
Placebo	-1.9

Intervention	hours (Median)
Modafinil	9.5

"Sleep efficiency during the down interval. The down interval signifies the period of time (in minutes) at night when subjects are in bed and trying to sleep. Sleep efficiency is calculated as (100*sleep minutes)/[time interval from sleep onset (as defined by the sleep latency) to sleep offset (the end of the last sleep episode in the Down interval)].~The time period was different for each patient, it was their duration of hospitalization. The first 48 hours patients were not on the study drug, so the reported least squares mean is an estimate of the mean for the subsequent time period where the patients received different therapies. These means are corrected for differences that might have existed during the first 48 hours. The results would be similar to the results attained from considering the mean during the first 48 hours as a baseline covariate in an Analysis of Covariance, but would be more robust to missing data." (NCT00814502)
Timeframe: Post-intervention, up to 3 weeks

Sleep Minutes

Intervention	percentage of sleep (see above) (Least Squares Mean)
Zolpidem CR	75.93
Placebo	75.30

"Total sleep minutes during the down period. The down interval signifies the period of time (in minutes) at night when subjects are in bed and trying to sleep.~The time period was different for each patient, it was their duration of hospitalization. The first 48 hours patients were not on the study drug, so the reported least squares mean is an estimate of the mean for the subsequent time period where the patients received different therapies. These means are corrected for differences that might have existed during the first 48 hours. The results would be similar to the results attained from considering the mean during the first 48 hours as a baseline covariate in an Analysis of Covariance, but would be more robust to missing data." (NCT00814502)
Timeframe: post-intervention, up to 3 weeks

Measures of Aggression, Psychosis, General Clinical Status, Cognitive Measures, Mood Symptoms

Intervention	sleep minutes (Least Squares Mean)
Zolpidem CR	443.71
Placebo	422.49

"Rating Scale for Aggressive Behavior in the Elderly (RAGE, 0-61); higher is worse.~Disruptive Behavior Rating Scales (DBRS, 0-105); higher is worse.~Neuropsychiatric Inventory (NPI, 0-144) - measures 12 different domains of neuropsychiatric symptoms such as delusions, hallucinations, anxiety, depression, apathy, etc.; higher is worse.~Montgomery-Asberg Depression Rating Scale (MADRS, 0-90); higher is worse.~Mini-mental state examination (MMSE, 0-30); higher is better.~The time period was different for each patient, it was their duration of hospitalization. The first 48 hours patients were not on the study drug, so the reported least squares mean is an estimate of the mean for the subsequent time period where the patients received different therapies. These means are corrected for differences that might have existed during the first 48 hours. The results would be similar to the results attained from considering the mean during the firs" (NCT00814502)
Timeframe: post-intervention, up to 3 weeks

Change From Baseline in Polysomnography-derived Total Sleep Time (TST) at Week 4

Intervention	units on a scale (Least Squares Mean)
	NPI Total Score	RAGE Total Score	DBRS Total Score	MMSE Total Score	MADRS Total Score
Placebo	18.64	5.82	22.47	21.57	22.56
Zolpidem CR	18.00	1.40	22.64	24.45	22.96

TST was measured at Baseline and at Week 4 in a sleep laboratory by polysomnography, during an 8-hour recording period beginning at participants' habitual bedtime. (NCT02750306)
Timeframe: Baseline and Week 4

Change From Baseline in Polysomnography-derived Wakefulness After Persistent Sleep Onset (WASO) at Week 4

Intervention	Minutes (Least Squares Mean)
Suvorexant	73.4
Placebo	45.2

WASO was measured at Baseline and at Week 4 in a sleep laboratory by polysomnography during an 8-hour recording period beginning at participants' habitual bedtime. (NCT02750306)
Timeframe: Baseline and Week 4

Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event

Intervention	Minutes (Least Squares Mean)
Suvorexant	-45.0
Placebo	-29.4

An adverse event (AE) is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product. (NCT02750306)
Timeframe: Up to 4 weeks

Percentage of Participants Who Experienced One or More Adverse Events

Intervention	Percentage of participants (Number)
Suvorexant	0.7
Placebo	0.7

Change From Baseline in Latency of Persistent Sleep After 4 Weeks of Treatment, Based on Actigraphy Recording.

Intervention	Percentage of participants (Number)
Suvorexant	22.5
Placebo	16.1

Change from baseline in latency of persistent sleep after 4 weeks of treatment, based on participants with valid baseline and week 4 actigraphy data (NCT01548287)
Timeframe: Baseline and Week 4.

Change From Baseline in Latency to Persistent Sleep After 4 Weeks of Treatment, Based on PSG Measurements.

Change From Baseline in Night Total Sleep Time After 4 Weeks of Treatment, Based on Actigraphy Recording.

Intervention	Minutes (Least Squares Mean)
AZD5213 Dose A	1.77
AZD5213 Dose B	9.84
AZD5213 Dose C	-6.85
Placebo	2.70

Intervention	Rank transformed duration (minutes) (Least Squares Mean)
AZD5213 Dose A	-2.23
AZD5213 Dose B	14.48
AZD5213 Dose C	-5.84
Placebo	-5.68

Change from baseline in night total sleep time after 4 weeks of treatment: assessed if valid baseline and week 4 actigraphy data (NCT01548287)
Timeframe: Baseline and Week 4.

Change From Baseline in Sleep Efficiency After 4 Weeks of Treatment, Based on Actigraphy Recording.

Intervention	Minutes (Least Squares Mean)
AZD5213 Dose A	7.07
AZD5213 Dose B	-12.42
AZD5213 Dose C	-18.97
Placebo	-7.51

Change from baseline in sleep efficiency after 4 weeks of treatment, based on participants with valid baseline and week 4 actigraphy data (NCT01548287)
Timeframe: Baseline and Week 4.

Change From Baseline in Sleep Efficiency After 4 Weeks of Treatment, Based on PSG Measurements.

Change From Baseline in Total Sleep Time (TST) After 4 Weeks of Treatment, Based on PSG Measurement.

Intervention	% (efficiency=% of time asleep) (Least Squares Mean)
AZD5213 Dose A	-0.05
AZD5213 Dose B	-3.20
AZD5213 Dose C	-1.92
Placebo	-1.83

Intervention	% change (Least Squares Mean)
AZD5213 Dose A	0.08
AZD5213 Dose B	-1.51
AZD5213 Dose C	-2.82
Placebo	0.96

Total sleep time (TST) is defined as the total time in minutes, that subjects were determined to be in a sleep state by polysomnography (PSG) measurement. (NCT01548287)
Timeframe: Baseline and Week 4.

Article	Year
Trazodone improves sleep parameters in Alzheimer disease patients: a randomized, double-blind, and placebo-controlled study. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2014, Volume: 22, Issue:12 Topics: Actigraphy; Aged; Aged, 80 and over; Alzheimer Disease; Cognition Disorders; Comorbidity; Double-Bli	2014
Trazodone and cognitive performance in Alzheimer disease. Journal of clinical psychopharmacology, 2015, Volume: 35, Issue:1 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognition; Cross-Over Studies; Double-Blind Method; Fema	2015
Circadian rhythm in Alzheimer disease after trazodone use. Chronobiology international, 2015, Volume: 32, Issue:9 Topics: Actigraphy; Activity Cycles; Aged; Aged, 80 and over; Alzheimer Disease; Female; Humans; Male; Sleep	2015
The influence of galantamine on reaction time, attention processes, and performance variability in elderly Alzheimer patients. Journal of clinical psychopharmacology, 2007, Volume: 27, Issue:2 Topics: Aged, 80 and over; Alzheimer Disease; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation;	2007
Behavioral effects of trazodone in Alzheimer's disease. The Journal of clinical psychiatry, 1994, Volume: 55, Issue:12 Topics: Affective Symptoms; Aged; Aggression; Alzheimer Disease; Anxiety; Female; Follow-Up Studies; Humans;	1994
Oral 5'-methyltetrahydrofolic acid in senile organic mental disorders with depression: results of a double-blind multicenter study. Aging (Milan, Italy), 1993, Volume: 5, Issue:1 Topics: Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Cognition; Dementia, Multi-Infarct	1993
Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology, 2000, Nov-14, Volume: 55, Issue:9 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Behavior Therapy; Double-Blind Method; Female; Haloperid	2000
Does behavioral improvement with haloperidol or trazodone treatment depend on psychosis or mood symptoms in patients with dementia? Journal of the American Geriatrics Society, 2001, Volume: 49, Issue:10 Topics: Aged; Alzheimer Disease; Analysis of Variance; Antidepressive Agents, Second-Generation; Antipsychot	2001
No long-term effect of behavioral treatment on psychotropic drug use for agitation in Alzheimer's disease patients. Journal of geriatric psychiatry and neurology, 2002,Summer, Volume: 15, Issue:2 Topics: Aged; Alzheimer Disease; Anti-Anxiety Agents; Antipsychotic Agents; Behavior Therapy; Caregivers; Fe	2002

Article	Year
Improved Sleep, Memory, and Cellular Pathological Features of Tauopathy, Including the NLRP3 Inflammasome, after Chronic Administration of Trazodone in rTg4510 Mice. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2022, 04-20, Volume: 42, Issue:16 Topics: Alzheimer Disease; Animals; Disease Models, Animal; Disease Progression; Humans; Inflammasomes; Male	2022
The antidepressant drug; trazodone inhibits Tau amyloidogenesis: Prospects for prophylaxis and treatment of AD. Archives of biochemistry and biophysics, 2020, 01-15, Volume: 679 Topics: Alzheimer Disease; Antidepressive Agents; Cell Line, Tumor; Humans; Molecular Dynamics Simulation; P	2020
Anticholinergic Burden and Functional Status in Older People with Cognitive Impairment: Results from the Regal Project. The journal of nutrition, health & aging, 2017, Volume: 21, Issue:4 Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinergic Antagonists; Cog	2017
The Global Music Approach to Dementia (GMA-D): evidences from a case report. Aging clinical and experimental research, 2018, Volume: 30, Issue:12 Topics: Aged, 80 and over; Alzheimer Disease; Female; Humans; Mental Status and Dementia Tests; Music; Music	2018
Long-Term Trazodone Use and Cognition: A Potential Therapeutic Role for Slow-Wave Sleep Enhancers. Journal of Alzheimer's disease : JAD, 2019, Volume: 67, Issue:3 Topics: Aged; Alzheimer Disease; Antidepressive Agents, Second-Generation; Case-Control Studies; Cognition;	2019
Treatment of Alzheimer's Disease: Trazodone, Sleep, Serotonin, Norepinephrine, and Future Directions. Journal of Alzheimer's disease : JAD, 2019, Volume: 67, Issue:3 Topics: Aged; Alzheimer Disease; Humans; Norepinephrine; Serotonin; Sleep; Trazodone	2019
Regression to the mean: implications for clinical trials of psychotropic agents in dementia. Current Alzheimer research, 2004, Volume: 1, Issue:4 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Behavior Therapy; Data Interpretat	2004
Gonadotrophin-releasing hormone agonist treatment of aggression in Alzheimer's disease: a case report. International psychogeriatrics, 2005, Volume: 17, Issue:2 Topics: Aged; Aggression; Alzheimer Disease; Amines; Antipsychotic Agents; Benzodiazepines; Cyclohexanecarbo	2005
[Trazodone for the treatment of behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease: a retrospective study focused on the aggression and negativism in caregiving situations]. No to shinkei = Brain and nerve, 2006, Volume: 58, Issue:6 Topics: Activities of Daily Living; Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Anti-Anxiety Age	2006
Coma in a patient with Alzheimer's disease taking low dose trazodone and gingko biloba. Journal of neurology, neurosurgery, and psychiatry, 2000, Volume: 68, Issue:5 Topics: Aged; Alzheimer Disease; Coma; Drug Interactions; Female; Ginkgo biloba; Humans; Plants, Medicinal;	2000
Nonsedating treatments for Alzheimer's patients with behavioral problems. The Journal of clinical psychiatry, 1992, Volume: 53, Issue:3 Topics: Alzheimer Disease; Buspirone; Fluoxetine; Humans; Selegiline; Sleep; Trazodone	1992
Serotonergic treatment for aggression in a Down's syndrome adult showing signs of Alzheimer's disease. Journal of mental deficiency research, 1991, Volume: 35 ( Pt 3) Topics: Aggression; Alzheimer Disease; Arousal; Brain; Combined Modality Therapy; Down Syndrome; Feeding Beh	1991
Medications to modify at-home behavior of Alzheimer's patients. Geriatrics, 1985, Volume: 40, Issue:12 Topics: Aged; Alzheimer Disease; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Behavior;	1985
Improvement in organically disturbed behavior with trazodone treatment. The Journal of clinical psychiatry, 1986, Volume: 47, Issue:4 Topics: Aged; Aggression; Alcohol Amnestic Disorder; Alzheimer Disease; Animals; Antipsychotic Agents; Human	1986

trazodone and Acute Confusional Senile Dementia